|
Dec 1
|
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
|
|
Nov 9
|
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
|
|
Sep 18
|
Decoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key Metrics
|